JPH10279437A - Hair cosmetic - Google Patents
Hair cosmeticInfo
- Publication number
- JPH10279437A JPH10279437A JP9098447A JP9844797A JPH10279437A JP H10279437 A JPH10279437 A JP H10279437A JP 9098447 A JP9098447 A JP 9098447A JP 9844797 A JP9844797 A JP 9844797A JP H10279437 A JPH10279437 A JP H10279437A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- blood flow
- extract
- cosmetic
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 49
- 239000002537 cosmetic Substances 0.000 title claims abstract description 44
- ONLRKTIYOMZEJM-UHFFFAOYSA-N n-methylmethanamine oxide Chemical compound C[NH+](C)[O-] ONLRKTIYOMZEJM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960003632 minoxidil Drugs 0.000 claims abstract description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 7
- 230000017531 blood circulation Effects 0.000 claims description 51
- 239000000284 extract Substances 0.000 claims description 43
- 230000001737 promoting effect Effects 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 13
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 12
- 150000002814 niacins Chemical class 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 34
- 201000004384 Alopecia Diseases 0.000 abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- -1 nicotinic acid compound Chemical class 0.000 abstract description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 238000013329 compounding Methods 0.000 abstract description 5
- 239000002304 perfume Substances 0.000 abstract description 5
- 150000001412 amines Chemical class 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 229960003512 nicotinic acid Drugs 0.000 abstract description 3
- 239000011664 nicotinic acid Substances 0.000 abstract description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract description 2
- 230000037396 body weight Effects 0.000 abstract description 2
- 239000000419 plant extract Substances 0.000 abstract description 2
- 150000005846 sugar alcohols Polymers 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 239000011701 zinc Substances 0.000 abstract description 2
- 229910052725 zinc Inorganic materials 0.000 abstract description 2
- 239000003086 colorant Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003405 preventing effect Effects 0.000 abstract 1
- 229940069762 swertia japonica extract Drugs 0.000 abstract 1
- 230000003779 hair growth Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 210000004761 scalp Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003676 hair preparation Substances 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000975 dye Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229950004580 benzyl nicotinate Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEYZWPRKKUGDCR-QBXMEVCASA-N Swertiamarin Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@]2(O)CCOC(=O)C2=CO1 HEYZWPRKKUGDCR-QBXMEVCASA-N 0.000 description 3
- HEYZWPRKKUGDCR-WRMJXEAJSA-N Swertiamarin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1 HEYZWPRKKUGDCR-WRMJXEAJSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 240000003889 Piper guineense Species 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940045870 sodium palmitate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000499950 Arthropodium cirratum Species 0.000 description 1
- DVHSOAIRLNJAJP-UHFFFAOYSA-N CCC(C)OOC(=O)c1cccnc1 Chemical compound CCC(C)OOC(=O)c1cccnc1 DVHSOAIRLNJAJP-UHFFFAOYSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 241000397426 Centroberyx lineatus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 235000003956 Luffa Nutrition 0.000 description 1
- 244000050983 Luffa operculata Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 241000183666 Nepsera aquatica Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000967294 Swertia japonica Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940107588 barberry extract Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000001599 crocus sativus l. flower extract Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940007062 eucalyptus extract Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003662 hair growth rate Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 229940076591 saffron extract Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、頭皮頭髪用化粧料
(以下,頭髪用化粧料という)に関する技術分野に属す
る発明である。より詳細には、優れた血流促進作用を有
し,かつ安全性にも優れる頭髪用化粧料に関する技術分
野に属し、本発明頭髪用化粧料は、特に医薬品,医薬部
外品又は化粧品の分野において用いられる。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention belongs to the technical field of scalp hair cosmetics (hereinafter referred to as hair cosmetics). More specifically, it belongs to the technical field of hair cosmetics having an excellent blood flow promoting action and also being excellent in safety, and the hair cosmetics of the present invention are particularly useful in the fields of pharmaceuticals, quasi-drugs or cosmetics. Used in
【0002】[0002]
【従来の技術】頭髪用化粧料には、様々な種類があり、
様々な頭皮頭髪状態に対応した製品が存在している。例
えば、頭皮状態によっては少なくとも頭皮部分の血流を
促進することにより、脱毛状態等の現状を改善し得る製
品が開発されている。頭皮における様々なトラブルは、
高齢化社会を迎えた今日では、社会的ストレスの増大も
伴って増加しつつあり、この頭皮におけるトラブルに対
応した毛髪化粧料の需要は急増している。一般に、頭部
の禿や脱毛,毛の細り,頭皮のかゆみ,フケ等の原因と
しては、毛根の皮脂腺等の器官における男性ホルモンの
活性化,毛包への血流量の低下,過剰な皮脂分泌,過酸
化脂質の生成及びストレス等が挙げられる。また、丈夫
で美しい毛髪を育てるうえで、十分な毛包への栄養補給
が出来ない場合、細毛ややせ毛の原因となる。毛包への
血流量の低下は、栄養不足や老廃物の排泄の機能の低下
を招く。2. Description of the Related Art There are various types of hair cosmetics.
There are products for various scalp hair conditions. For example, depending on the scalp condition, a product that can improve the current condition such as a hair loss condition by promoting blood flow at least in the scalp portion has been developed. Various troubles on the scalp
In today's aging society, social stress is increasing, and the demand for hair cosmetics corresponding to the scalp trouble is increasing rapidly. In general, baldness and alopecia of the head, thinning of hair, itching of the scalp, dandruff, etc. are caused by activation of androgens in organs such as sebaceous glands of hair roots, decreased blood flow to hair follicles, excessive secretion of sebum. , Lipid peroxide formation and stress. In addition, when sufficient hair follicles cannot be supplied with nutrients to grow durable and beautiful hair, fine hair and thin hair may be caused. Decreased blood flow to the hair follicles leads to nutritional deficiency and reduced excretion of waste products.
【0003】このような観点から、少なくとも頭皮にお
ける血流機能の低下を改善することは、頭皮及び頭髪の
トラブルを解決する上で欠かせないポイントとなる。従
来の頭髪用化粧料は、一般的にこれらの禿や脱毛の原因
と考えられる要素を取り除いたり、軽減する作用を持つ
物質を配合したものである。例えば、ビタミンB,ビタ
ミンE等のビタミン類、セリン,メチオニン等のアミノ
酸類、センブリエキス,アセチルコリン誘導体等の血管
拡張剤、紫根エキス,ヒノキチオール等の抗炎症剤、エ
ストラジオール等の女性ホルモン剤、セファランチン等
の皮膚機能亢進剤等が配合され、禿や脱毛、毛髪の細り
の予防及び治療に用いられている。[0003] From such a viewpoint, improvement of at least a decrease in blood flow function in the scalp is an indispensable point in solving troubles in the scalp and hair. Conventional hair cosmetics generally contain a substance having an action of removing or reducing factors considered to be the cause of baldness and hair loss. For example, vitamins such as vitamin B and vitamin E, amino acids such as serine and methionine, vasodilators such as assembly extract and acetylcholine derivative, anti-inflammatory agents such as purple root extract and hinokitiol, female hormones such as estradiol, cepharanthin and the like Are used in the prevention and treatment of baldness, hair loss and hair thinning.
【0004】[0004]
【発明が解決しようとする課題】しかしながら、これら
の成分を少量のみ頭髪用化粧料中に配合しても十分な効
果を得ることは難しく、逆に多く配合すると使用部分及
びその周辺に不快な刺激感や発赤を伴う傾向が強まり、
自ずと配合量には限界があった。However, it is difficult to obtain a sufficient effect even if only a small amount of these components is incorporated into the cosmetic for hair. There is a tendency to have a feeling and redness,
Naturally, the amount was limited.
【0005】そこで本発明が解決すべき課題は、優れた
血流促進効果を有し、かつ安全性にも優れる頭髪用化粧
料を提供することである。The problem to be solved by the present invention is to provide a cosmetic for hair which has an excellent blood flow promoting effect and is also excellent in safety.
【0006】[0006]
【課題を解決するための手段】本発明者は、この課題の
解決に向けて鋭意検討を行った。その結果、従来から使
用している血流促進剤と特定のアミンオキシドとを組み
合わせて配合することにより、優れた脱毛防止効果や発
毛効果,毛髪の細りの防止効果を有し、かつ安全性にも
優れる頭髪用化粧料が提供されることを見出し、本発明
を完成した。Means for Solving the Problems The present inventor has made intensive studies to solve this problem. As a result, by combining the conventionally used blood flow enhancer with a specific amine oxide, it has excellent hair loss prevention effect, hair growth effect, hair thinning prevention effect, and safety. The present inventors have found that a hair cosmetic composition that is excellent in hair quality is provided, and completed the present invention.
【0007】すなわち本発明は、血流促進剤及び下記式
(I)で表されるジメチルアミンオキシドThat is, the present invention provides a blood flow enhancer and dimethylamine oxide represented by the following formula (I):
【化2】 を含んでなる頭髪用化粧料を提供する。Embedded image And a hair cosmetic composition comprising:
【0008】また、この血流促進成分が、ニコチン酸
類,ミノキシジル類及びセンブリ抽出物からなる群の血
流促進成分から選ばれる1種又は2種以上の血流促進成
分である場合が特に所期の効果を良好に発揮し得る。It is particularly desirable that the blood flow promoting component is one or more blood flow promoting components selected from the group consisting of nicotinic acids, minoxidil and assembly extracts. The effect of can be exhibited favorably.
【0009】[0009]
【発明の実施の形態】以下、本発明の実施の形態につい
て説明する。本発明頭髪用化粧料は、血流促進成分と上
記のジメチルオキシド(I)とを組み合わせて配合する
ことにより、所期の効果を発揮する頭髪用化粧料であ
る。本発明頭髪用化粧料中に配合可能な血流促進成分
は、それを皮膚上に塗布することにより,人体の血流を
促進し、かつ外用剤の配合成分として安全性上問題がな
い限りにおいて、特に限定されるものではなく、その作
用機序も問われるべきものではない。Embodiments of the present invention will be described below. The cosmetic for hair of the present invention is a cosmetic for hair that exhibits a desired effect by being combined with a blood flow promoting component and the above-mentioned dimethyl oxide (I) in combination. The blood flow-promoting component that can be incorporated into the hair cosmetic composition of the present invention, by applying it on the skin, promotes the blood flow of the human body, and as long as there is no safety problem as a component of the external preparation. However, the present invention is not particularly limited, and its action mechanism should not be questioned.
【0010】具体的には、ニコチン酸及びその誘導体
(本願においては、これをニコチン酸類と定義する)、
ミノキシジル並びにその誘導体及びその類縁体(本願に
おいては、これをミノキシジル類と定義する)、センブ
リ抽出物、セファランチン、ビタミンE類、γ−オリザ
ノール,アルコキシカルボニルピリジンN−オキシド、
塩化カプロニウム、アセチルコリン及びその誘導体等の
頭髪化粧料に血流促進成分として通常配合されているも
のを適宜選択することができる。また、これらの血流促
進成分を単独で本発明頭髪用化粧料に配合することも可
能であるが、2種以上を組み合わせて配合することも可
能である。Specifically, nicotinic acid and its derivatives (this is defined as nicotinic acids in the present application),
Minoxidil and its derivatives and analogs thereof (this is defined as minoxidil in the present application), assembly extract, cepharanthin, vitamin Es, γ-oryzanol, alkoxycarbonylpyridine N-oxide,
Those usually compounded as a blood flow promoting ingredient in hair cosmetics such as capronium chloride, acetylcholine and derivatives thereof can be appropriately selected. In addition, these blood flow promoting components can be used alone in the cosmetic for hair of the present invention, but they can also be used in combination of two or more.
【0011】これらの血流促進成分のうちでも特に、ニ
コチン酸類,ミノキシジル類及び/又はセンブリ抽出物
を選択して本発明頭髪用化粧料中に配合することが好ま
しい。Among these blood flow promoting components, it is particularly preferable to select nicotinic acids, minoxidil and / or assembly extracts and blend them into the cosmetic for hair of the present invention.
【0012】ニコチン酸誘導体としては、例えばニコチ
ン酸ベンジルエステル,ニコチン酸トコフェロールエス
テル,ニコチン酸β−ブトキシエステル,ニコチン酸ア
ミド等を挙げることができる。Examples of the nicotinic acid derivative include benzyl nicotinate, tocopherol nicotinate, β-butoxy nicotinate, nicotinamide and the like.
【0013】これらのニコチン酸誘導体のうち、ニコチ
ン酸ベンジルエステル,ニコチン酸アミド等は現在市販
されている。また、その他のニコチン酸誘導体は、通常
公知の方法で製造することができる。Of these nicotinic acid derivatives, nicotinic acid benzyl ester, nicotinic amide and the like are currently commercially available. Other nicotinic acid derivatives can be produced by a generally known method.
【0014】またミノキシジルは、末梢血管拡張作用を
有し、難治性の高血圧症の治療に用いられてきたが、そ
の副作用として多毛症が認められたことから、局所外用
剤として利用されるに至った物質であり(米国特許第4
139619号,同第4596812号)、その化学名
は6−(1−ピメリジニル)−2,4−ピリミジンアミ
ン−3−オキサイドである。[0014] Minoxidil has a peripheral vasodilatory effect and has been used for the treatment of intractable hypertension. However, since hirsutism was recognized as a side effect thereof, it has been used as a topical external preparation. (US Patent No. 4)
139,819 and 4,596,812), the chemical name of which is 6- (1-pimelidinyl) -2,4-pyrimidineamine-3-oxide.
【0015】このミノキシジル誘導体として、このミノ
キシジルの塩等を挙げることが可能であり、ミノキシジ
ル類縁体としてはミノキシジルの抱合体を挙げることが
できる。これらのミノキシジル類は現在市販されてお
り、また通常公知の方法で製造することが可能である。Examples of the minoxidil derivative include salts of the minoxidil, and examples of the minoxidil analogs include conjugates of minoxidil. These minoxidils are currently commercially available, and can be usually produced by a known method.
【0016】センブリ抽出物は、リンドウ科植物のセン
ブリ(swertia japonica Makino )の苦味配糖体を含有
するエキス(主成分はスウェルチアマリンであり、本発
明においては、このスウェルチアマリンもセンブリ抽出
物に含まれるものとする)で、皮膚の毛細血管を拡張し
て血流を促進するといわれている血流促進剤であり、市
販されている。The extract of swallowtail is an extract containing the bitter glycoside of swertia japonica Makino (the main component is swertiamarin). In the present invention, the extract of swertiamarin is also an extract of swertiamarin. The blood flow promoting agent is said to promote blood flow by expanding the capillaries of the skin, and is commercially available.
【0017】本発明頭髪用化粧料における上記の血流促
進成分の配合量は、頭髪用化粧料全体に対して0.00
1重量%以上,5.0重量%以下であり、同0.01重
量%以上,2.0重量%以下が好ましい。The amount of the blood flow promoting component in the cosmetic for hair of the present invention is 0.000 to the total amount of the cosmetic for hair.
It is 1% by weight or more and 5.0% by weight or less, preferably 0.01% by weight or more and 2.0% by weight or less.
【0018】この配合量が頭髪用化粧料全体に対して
0.001重量%未満では十分な血流促進効果が発揮さ
れず好ましくなく、同5.0重量%を超えて配合すると
皮膚刺激等が伴う等,安全性の側面から問題が生じるお
それがある。If the amount is less than 0.001% by weight based on the total weight of the hair cosmetic composition, a sufficient blood flow-promoting effect is not exhibited, which is not preferable. If the amount exceeds 5.0% by weight, skin irritation and the like may occur. This may cause problems from the aspect of safety.
【0019】上記の血流促進成分と共に本発明毛髪化粧
料中に配合される、上記ジメチルアミンオキシド(I)
は通常公知のアミンオキシドの製造方法に従って製造す
ることができる。その一例を示せば、概ね以下の工程に
従って製造することができる。The above-mentioned dimethylamine oxide (I), which is incorporated into the hair cosmetic composition of the present invention together with the above-mentioned blood flow promoting component.
Can be produced according to a known amine oxide production method. If an example is shown, it can be manufactured generally according to the following steps.
【化3】 通常、このように製造したジメチルアミンオキシド
(I)は、再結晶法等の通常公知の精製法による精製工
程を経て本発明頭髪用化粧料中に配合する。Embedded image Usually, the dimethylamine oxide (I) thus produced is incorporated into the cosmetic for hair of the present invention through a purification step by a generally known purification method such as a recrystallization method.
【0020】本発明頭髪用化粧料中におけるこのジメチ
ルアミンオキシド(I)の配合量は、頭髪用化粧料全体
に対して0.0001重量%以上,20.0重量%以下
であり、同0.05重量%以上,5.0重量%以下が好
ましい。The amount of dimethylamine oxide (I) in the cosmetic for hair of the present invention is 0.0001% by weight or more and 20.0% by weight or less based on the total amount of the cosmetic for hair. It is preferably from 05% by weight to 5.0% by weight.
【0021】この配合量が頭髪用化粧料全体に対して
0.0001重量%未満では、十分な血流促進効果を発
揮することができず好ましくなく、同20.0重量%を
超えて配合すると、製剤上,また皮膚刺激性が生ずる等
の点から好ましくない。When the amount is less than 0.0001% by weight based on the total weight of the cosmetic for hair, a sufficient blood flow promoting effect cannot be exhibited, which is not preferable. It is not preferable from the viewpoints of, for example, the preparation and skin irritation.
【0022】このようにして、上記血流促進成分と上記
ジメチルアミンオキシド(I)とを組み合わせて配合す
ることにより、優れた血流促進効果を有し、安全性にも
優れる本発明頭髪用化粧料が提供される。なお、本発明
頭髪用化粧料中には、通常頭髪用化粧料中に配合される
薬効成分を、その薬効成分が有する一般的な効果を発揮
させる目的のために、本発明の所期の効果を損なわない
限りにおいて配合することも可能である。By combining the above-mentioned blood flow-promoting component and the above-mentioned dimethylamine oxide (I) in combination as described above, the present invention has a superior blood flow-promoting effect and is also excellent in safety. Fees are provided. Incidentally, in the hair cosmetic of the present invention, the medicinal component usually blended in the hair cosmetic, for the purpose of exerting the general effect of the medicinal component, the intended effect of the present invention Can be blended as long as is not impaired.
【0023】例えば、セリン,メチオニン,アルギニン
等のアミノ酸類等を本発明頭髪用化粧料中に配合するこ
ともできる。For example, amino acids such as serine, methionine and arginine can be incorporated into the cosmetic for hair of the present invention.
【0024】また、通常頭髪用化粧料中に配合される植
物抽出物、例えばアルテア抽出物,ヨクイニン抽出物,
ペパーミント抽出物,ヨウテイ抽出物,トウガラシ抽出
物,アロエ抽出物,クコ抽出物,ヨモギ抽出物,イネ抽
出物,マンケイシ抽出物,マンネンロウ抽出物,コッサ
イホ抽出物,エニシダ抽出物,リンドウ抽出物,タンジ
ン抽出物,ヘチマ抽出物,キキョウ抽出物,マツ抽出
物,クジン抽出物,トウキ抽出物,ベニバナ抽出物,メ
ギ抽出物,ビンロウジ抽出物,ユーカリ抽出物,カゴソ
ウ抽出物,モクソウ抽出物,ゴシツ抽出物,サイコ抽出
物,チャ抽出物,カンゾウ抽出物,ホップ抽出物,キク
抽出物,セネガ抽出物,ゴマ抽出物,センキュウ抽出
物,カシュウ抽出物,カッコン抽出物,マイカイカ抽出
物,サフラン抽出物,ローズマリー抽出物,ジオウ抽出
物,ゼニアオイ抽出物等を本発明頭髪用化粧料中に配合
することができる。In addition, plant extracts, such as Altea extract, yoquinin extract, and the like, which are usually incorporated in hair cosmetics,
Peppermint extract, ginkgo biloba extract, capsicum extract, aloe extract, wolfberry extract, mugwort extract, rice extract, mankeishii extract, mannenwa extract, kossaiho extract, enishida extract, gentian extract, tangsin extract , Luffa extract, fennel extract, pine extract, kudin extract, touki extract, safflower extract, barberry extract, areca extract, eucalyptus extract, kagosou extract, mokusou extract, gossip extract, Psycho extract, tea extract, licorice extract, hop extract, chrysanthemum extract, senega extract, sesame extract, senkyu extract, cashew extract, cuckoo extract, Maikaika extract, saffron extract, rosemary An extract, a dirt extract, a mallow extract, and the like can be incorporated into the cosmetic for hair of the present invention.
【0025】また、亜鉛若しくはその誘導体;乳酸若し
くはそのアルキルエステル等;クエン酸等の有機酸類;
トラネキサム酸等のプロテアーゼ阻害剤;オリーブ油,
スクワラン,流動パラフィン,イソプロピルミリステー
ト,高級脂肪酸,高級アルコール等の油分;グリセリ
ン,プロピレングリコール等の多価アルコール;その他
界面活性剤,保湿剤,増粘剤,香料,酸化防止剤,紫外
線吸収剤,色素,エタノール,水等を本発明の所期の効
果を損なわない範囲で適宜配合することができる。Also, zinc or a derivative thereof; lactic acid or an alkyl ester thereof; organic acids such as citric acid;
Protease inhibitors such as tranexamic acid; olive oil,
Oils such as squalane, liquid paraffin, isopropyl myristate, higher fatty acids and higher alcohols; polyhydric alcohols such as glycerin and propylene glycol; other surfactants, humectants, thickeners, fragrances, antioxidants, ultraviolet absorbers, Dyes, ethanol, water, and the like can be appropriately blended within a range that does not impair the intended effect of the present invention.
【0026】本発明頭髪用化粧料の形態は、液状,乳
液,軟膏等外皮に適用可能な性状のものであれば問われ
るものではなく、必要に応じて適宜基剤成分等を配合し
て所望の形態の本発明頭髪用化粧料を調製することがで
きる。また、本発明頭髪用化粧料は、医薬品,医薬部外
品又は化粧料等の多様な分野において適用可能である。The form of the cosmetic for hair of the present invention is not particularly limited as long as it can be applied to the outer skin such as liquid, emulsion, ointment and the like. Of the present invention can be prepared. Further, the cosmetic for hair of the present invention can be applied in various fields such as pharmaceuticals, quasi-drugs, and cosmetics.
【0027】本発明頭髪用化粧料は、少なくとも頭皮の
血流を促進させること解決可能な目的、例えば脱毛やフ
ケ,かゆみ等の治療や予防に用いることが可能であり、
例えば男性性脱毛症の治療や予防、女性に多いびまん性
脱毛症の治療や予防、円形脱毛症の治療等に広く用いる
ことができる。なお、ここに示した目的は例示であり、
これらの目的に本発明頭髪用化粧料の適用可能な疾患が
限定されるものではない。The cosmetic for hair of the present invention can be used for at least a purpose that can be solved to promote blood flow of the scalp, for example, treatment or prevention of hair loss, dandruff, itching, etc.
For example, it can be widely used for treatment and prevention of androgenetic alopecia, treatment and prevention of diffuse alopecia common to women, treatment of alopecia areata and the like. In addition, the purpose shown here is an example,
The diseases applicable to the cosmetic for hair of the present invention are not limited to these objects.
【0028】本発明頭髪用化粧料は、概ね皮膚に直接塗
布又は散布する等の経皮投与により投与される(なお、
本発明頭髪用化粧料においては,上記必須成分の組み合
わせ配合により、成分の経皮吸収が促進される)。そし
て、本発明頭髪用化粧料の投与量は、年齢,脱毛の程度
等の個人差やその製剤形態に応じて適宜決定されるべき
ものであるが、一般の大人に対する投与量は、体重1Kg
当り0.001〜100mg/日、好ましくは0.1〜1
0mg/日であり、これを1日2〜4回に分けて投与する
ことができる。The hair cosmetic composition of the present invention is generally administered by transdermal administration such as directly applying or spraying on the skin (in addition,
In the hair cosmetic of the present invention, the percutaneous absorption of the components is promoted by the combination of the above essential components). The dosage of the cosmetic for hair of the present invention should be appropriately determined according to individual differences such as age and the degree of hair loss and the form of the preparation, but the dosage for general adults is 1 kg body weight.
0.001-100 mg / day, preferably 0.1-1
0 mg / day, which can be administered in 2 to 4 times a day.
【0029】[0029]
【実施例】以下、実施例等により本発明をより具体的に
説明するが、これらの実施例等により本発明の技術的範
囲が限定されるべきものではない。まず、各実施例等の
開示に先立ち、これらの実施例等の養毛効果を検討する
ための試験について説明する。EXAMPLES Hereinafter, the present invention will be described more specifically with reference to Examples and the like, but the technical scope of the present invention should not be limited by these Examples and the like. First, prior to disclosure of each embodiment, tests for examining the hair-growing effect of these embodiments will be described.
【0030】1.レーザードップラー法による血流量試
験 ALF−2100(アドバンス社製)を用いてレーザー
ドップラー法、すなわち皮膚にレーザーを当て,その反
射光のずれ(ドップラー効果)を利用して血流量の変化
を測定する方法により試験品の塗布前後での血流量の変
化を測定した。すなわち、下記の実施例1〜10・比較
例1〜5は各群6名のパネルを用いて、これらのサンプ
ル1mlを前腕内側2cm×2cm角に塗布した。試料塗布3
0分後に再度血流量を測定して、その変化の度合いによ
って血流促進効果を評価した。1. Blood flow test by laser Doppler method
Experience ALF-2100 (manufactured by Advance Co., Ltd.) laser Doppler method using, i.e. applying a laser to the skin, the deviation of the reflected light (Doppler effect) before and after the test article coated by a method of measuring changes in blood flow using a The change in blood flow was measured. That is, in the following Examples 1 to 10 and Comparative Examples 1 to 5, 1 ml of each sample was applied to a 2 cm × 2 cm square inside the forearm using a panel of 6 persons in each group. Sample application 3
After 0 minute, the blood flow was measured again, and the blood flow promoting effect was evaluated based on the degree of the change.
【0031】それぞれの測定は各パネルについて5回行
い、6名の平均値の度合いから以下のように表示した。 +++:血流量が3倍以上増加しており,極めて著しい
効果が認められた。 ++:血流量が2倍以上増加しており,著しい効果が認
められた。 +:血流量が1.5倍以上増加しており,かなりの効果
が認められた。 ±:血流量が1.0〜1.5倍増加しており,やや効果
が認められた。 −:血流量の増加が認められず,効果が認められなかっ
た。Each measurement was carried out five times for each panel, and the results were indicated as follows based on the average value of the six persons. +++: The blood flow increased three times or more, and an extremely remarkable effect was observed. ++: The blood flow increased twice or more, and a remarkable effect was observed. +: The blood flow increased 1.5 times or more, and a considerable effect was recognized. ±: The blood flow increased by 1.0 to 1.5 times, and a slight effect was observed. -: No increase in blood flow was observed, and no effect was observed.
【0032】2.発毛試験 下記の実施例1〜10・比較例1〜5のサンプルにおけ
る発毛試験を、毛周期の休止期にあるC3H/HeNC
rマウスを用い、小川らの方法(ノーマル アンド ア
ブノーマル エピダーマル ディファレンシェーション
(Normal and Abnormal Epidermal Differentiation,
M.Seiji及びI.A.Bernstein 編集、第159〜170 頁,19
82年,東大出版)に従い行った。2. Hair growth test The hair growth test for the samples of Examples 1 to 10 and Comparative Examples 1 to 5 described below was performed using C3H / HeNC in the telogen of the hair cycle.
Using a mouse, the method of Ogawa et al. (Normal and Abnormal Epidermal Differentiation,
Edited by M. Seiji and IABernstein, pp. 159-170, 19
1982, published by The University of Tokyo).
【0033】すなわち、マウス1群10匹とし、無塗
布,実施例1〜10及び比較例1〜5の各群に分け、バ
リカン及びシェーバーでマウスの背部を剃毛し、それぞ
れのサンプルを1日1回、0.1mlずつ塗布した。各サ
ンプルの発毛効果は、30日後のマウス背部の発毛部分
の面積比(発毛部分の面積/剃毛部分の面積×100=
発毛率)によって評価した。That is, a group of 10 mice was uncoated, divided into groups of Examples 1 to 10 and Comparative Examples 1 to 5, the back of the mouse was shaved with a clipper and a shaver, and each sample was collected for 1 day. One time, 0.1 ml was applied. The hair growth effect of each sample was determined by calculating the area ratio of the hair growth part on the back of the mouse after 30 days (the area of the hair growth part / the area of the shaved part × 100 =
Hair growth rate).
【0034】〔実施例1〜10,比較例1〜5〕第1表
(実施例1〜10)及び第2表(比較例1〜5)に示し
た配合成分の血流促進ローションを後述する製法に従っ
て調製し、上記血流量試験及び発毛試験を行った。その
結果も併せて第1表及び第2表に記載する。Examples 1 to 10, Comparative Examples 1 to 5 The blood flow promoting lotions of the components shown in Table 1 (Examples 1 to 10) and Table 2 (Comparative Examples 1 to 5) will be described later. It was prepared according to the manufacturing method, and the above blood flow test and hair growth test were performed. The results are also shown in Tables 1 and 2.
【0035】[0035]
【表1】 [Table 1]
【0036】[0036]
【表2】 [Table 2]
【0037】<製法>95%エタノールに、薬剤(油溶
性),グリセリン,硬化ヒマシ油EO(20モル)及び
香料を溶解し、次いで精製水に乳酸,乳酸ナトリウム,
色素及び薬剤(水溶性)を添加後溶解した。この水相を
前記アルコール相に添加後、攪拌して透明液状のローシ
ョンを得た。<Production Method> A drug (oil-soluble), glycerin, hydrogenated castor oil EO (20 mol) and a flavor are dissolved in 95% ethanol, and then lactic acid, sodium lactate,
The dye and drug (water-soluble) were added and dissolved. This aqueous phase was added to the alcohol phase and stirred to obtain a transparent liquid lotion.
【0038】この結果より、ニコチン酸アミド,ミノキ
シジル又はセンブリ抽出物のいずれかの血流促進成分と
ジメチルアミンオキシド(I)とを配合した実施例の血
流促進ローションには、血流量を使用後増加させる血流
促進効果及び発毛効果が顕著に認められたが、これらの
血流促進成分とジメチルアミンオキシド(I)のいずれ
か一方のみ配合した比較例の養毛ローションは、たとえ
これらの成分を相当量配合しても、血流量の増加効果及
び発毛効果共に、上記実施例の結果と比べると著しく劣
っていた。From these results, it is found that the blood flow promoting lotion of the example in which the blood flow promoting component of any of nicotinamide, minoxidil or assembly extract and dimethylamine oxide (I) are blended, uses the blood flow rate after use. Although the blood flow promoting effect and the hair growth effect to increase were remarkably recognized, the hair growth lotion of the comparative example containing only one of these blood flow promoting components and dimethylamine oxide (I) was not affected by these components. When a large amount of was added, both the effect of increasing blood flow and the effect of growing hair were significantly inferior to the results of the above examples.
【0039】すなわち、上記血流促進成分とジメチルア
ミンオキシド(I)とを組み合わせて配合した本発明頭
髪用化粧料においては、相乗的な血流量増加及び発毛効
果が顕著に認められることが明らかになった。このこと
は、少量の有効成分であっても本発明頭髪用化粧料にお
いては所望する血流促進効果を得ることが可能であり、
血流促進成分を多量に配合することによって惹起され
る、塗布部及びその周辺部の不快な刺激感や発赤を防ぐ
ことが可能になったことを示すものである。That is, in the hair cosmetic composition of the present invention in which the above blood flow promoting component and dimethylamine oxide (I) are combined in combination, it is apparent that a synergistic increase in blood flow and a hair growth effect are remarkably observed. Became. This means that even with a small amount of the active ingredient, it is possible to obtain a desired blood flow promoting effect in the hair cosmetic of the present invention,
This indicates that it became possible to prevent an unpleasant irritant feeling and redness of the application part and its peripheral part caused by blending a large amount of the blood flow promoting component.
【0040】以下、さらに他の本発明頭髪用化粧料の処
方例を示す。 〔実施例11〕 薬用トニック 配合量(重量%) 95%エタノール 60.0 ジメチルアミンオキシド(I) 8.0 ニコチン酸β−ブトキシエチルエステル 0.03 酢酸トコフェロール 1.0 プロピレングリコール 3.0 コハク酸 適 量 香料及び色素 適 量 ポリオキシエチレン硬化ヒマシ油5モル付加物 1.5 精製水 残 量Hereinafter, still another formulation example of the hair cosmetic composition of the present invention will be described. [Example 11] Medicinal tonic Compounding amount (% by weight) 95% ethanol 60.0 Dimethylamine oxide (I) 8.0 Nicotinic acid β-butoxyethyl ester 0.03 Tocopherol acetate 1.0 Propylene glycol 3.0 Succinic acid Appropriate amount Perfume and pigment Appropriate amount Polyoxyethylene hydrogenated castor oil 5 mol adduct 1.5 Purified water balance
【0041】<製法>95%エタノールに、薬剤(油溶
性),プロピレングリコール,ポリオキシエチレン硬化
ヒマシ油5モル付加物及び香料を溶解し、次いで精製水
にコハク酸,色素及び薬剤(水溶性)を添加後溶解し
た。この水相を前記アルコール相に添加後,攪拌して、
透明液状のローションを得た。<Production method> In 95% ethanol, a drug (oil-soluble), propylene glycol, a polyoxyethylene hydrogenated castor oil 5 mol adduct and a fragrance are dissolved, and then succinic acid, a dye and a drug (water-soluble) are dissolved in purified water. Was dissolved after the addition. After adding this aqueous phase to the alcohol phase, stirring,
A clear liquid lotion was obtained.
【0042】この本発明頭髪用化粧料に上記試験を行っ
たところ、血流量試験においてはかなりの効果が認めら
れ、発毛試験においては85%の効果が認められた。When the above-mentioned test was carried out on the cosmetic for hair of the present invention, a considerable effect was recognized in the blood flow test, and an 85% effect was recognized in the hair growth test.
【0043】 〔実施例12〕 養毛ローション 配合量(重量%) 95%エタノール 70.0 ジメチルアミンオキシド(I) 4.0 ミノキシジル 1.0 セファランチン 0.5 トウガラシチンキ 0.5 ソルビトール 10.0 リン酸 0.1 リン酸ナトリウム 0.2 香料及び色素 適 量 ラウリル硫酸ナトリウム 2.0 精製水 残 量Example 12 Hair Nourishing Lotion Compounding amount (% by weight) 95% ethanol 70.0 Dimethylamine oxide (I) 4.0 Minoxidil 1.0 Cepharanthin 0.5 Pepper tincture 0.5 Sorbitol 10.0 Phosphorus Acid 0.1 Sodium phosphate 0.2 Perfume and pigment Suitable amount Sodium lauryl sulfate 2.0 Purified water balance
【0044】<製法>95%エタノールに、薬剤(油溶
性),トウガラシチンキ及び香料を溶解し、次いで精製
水にリン酸,リン酸ナトリウム,ソルビトール,ラウリ
ル硫酸ナトリウム,色素及び薬剤(水溶性)を添加後,
溶解した。この水相を前記アルコール相に添加後、攪拌
して透明液状のローションを得た。<Production method> A drug (oil-soluble), pepper tincture and perfume are dissolved in 95% ethanol, and then phosphoric acid, sodium phosphate, sorbitol, sodium lauryl sulfate, a dye and a drug (water-soluble) are dissolved in purified water. After the addition,
Dissolved. This aqueous phase was added to the alcohol phase and stirred to obtain a transparent liquid lotion.
【0045】この本発明頭髪用化粧料に上記試験を行っ
たところ、血流量試験においては極めて著しい効果が認
められ、発毛試験においては95%の効果が認められ
た。When the above test was carried out on the cosmetic for hair of the present invention, a remarkable effect was observed in the blood flow test, and a 95% effect was observed in the hair growth test.
【0046】 〔実施例13〕 養毛ローション 配合量(重量%) 95%エタノール 45.0 ジメチルアミンオキシド(I) 10.0 カフェイン 0.15 ニコチン酸ベンジル 0.05 アスパラギン酸 0.05 パラブチレングリコール 2.0 マルチトール 8.0 ポリエチレングリコール400 2.0 プロピルパラベン 0.05 ヘキサメタリン酸ソーダ 適 量 パルミチン酸ナトリウム 0.3 香料及び色素 適 量 精製水 残 量Example 13 Hair Nourishing Lotion Compounding Amount (% by Weight) 95% Ethanol 45.0 Dimethylamine Oxide (I) 10.0 Caffeine 0.15 Benzyl Nicotinate 0.05 Aspartic Acid 0.05 Parabutylene Glycol 2.0 Maltitol 8.0 Polyethylene glycol 400 2.0 Propyl paraben 0.05 Sodium hexametaphosphate Appropriate amount Sodium palmitate 0.3 Appropriate flavor and pigment Appropriate amount
【0047】<製法>95%エタノールに、薬剤(油溶
性),パラブチレングリコール,ポリエチレングリコー
ル400,プロピルパラベン及び香料を溶解し、次いで
精製水にアスパラギン酸,マルチトール,ヘキサメタリ
ン酸ソーダ,パルミチン酸ナトリウム及び色素を添加
後、溶解した。この水相を前記アルコール相に添加後、
攪拌して透明液状のローションを得た。<Production method> A drug (oil-soluble), parabutylene glycol, polyethylene glycol 400, propylparaben and a flavor are dissolved in 95% ethanol, and then aspartic acid, maltitol, sodium hexametaphosphate and sodium palmitate are dissolved in purified water. After the addition of the dye and the dye, the mixture was dissolved. After adding this aqueous phase to the alcohol phase,
By stirring, a clear liquid lotion was obtained.
【0048】この本発明頭髪用化粧料に上記試験を行っ
たところ、血流量試験においては極めて著しい効果が認
められ、発毛試験においては90%の効果が認められ
た。When the above-mentioned test was carried out on the cosmetic for hair of the present invention, an extremely remarkable effect was recognized in the blood flow test, and a 90% effect was recognized in the hair growth test.
【0049】 〔実施例14〕 頭皮マッサージ剤 配合量(重量%) 95%エタノール 45.0 ジメチルアミンオキシド(I) 1.0 ニコチン酸アミド 0.8 ニコチン酸ベンジル 0.05 ダイナマイトグリセリン 5.0 1,3−ブチレングリコール 8.0 ジプロピレングリコール 4.5 増粘剤 3.0 メチルパラベン 0.2 香料及び色素 適 量 精製水 残 量Example 14 Scalp Massage Agent Compounding Amount (% by Weight) 95% Ethanol 45.0 Dimethylamine Oxide (I) 1.0 Nicotinamide 0.8 Benzyl Nicotinate 0.05 Dynamite Glycerin 5.0 1 , 3-butylene glycol 8.0 dipropylene glycol 4.5 thickener 3.0 methyl paraben 0.2 perfume and pigment
【0050】<製法>精製水の一部に増粘剤を加え,溶
解増粘させた後、別に精製水に溶かした色素を加えた。
この水相に、ダイナマイトグリセリン、1,3−ブチレ
ングリコール,ジプロピレングリコールを加えて混合し
たところへ、95%エタノールに溶解させた薬剤,メチ
ルパラベン及び香料を添加後、攪拌してジェル状の頭皮
マッサージ剤を得た。<Production Method> A thickener was added to a part of purified water to dissolve and thicken, and then a dye dissolved in purified water was added separately.
Dynamite glycerin, 1,3-butylene glycol, and dipropylene glycol were added to and mixed with the aqueous phase. A drug dissolved in 95% ethanol, methylparaben, and a fragrance were added, and the mixture was stirred to give a gel-like scalp massage. Agent was obtained.
【0051】この本発明頭髪用化粧料に上記試験を行っ
たところ、血流量試験においては著しい効果が認めら
れ、発毛試験においては90%の効果が認められた。When the above-mentioned test was carried out on the cosmetic for hair of the present invention, a remarkable effect was recognized in the blood flow test, and a 90% effect was recognized in the hair growth test.
【0052】[0052]
【発明の効果】本発明により、優れた血流促進効果を有
し、かつ安全性にも優れる頭髪用化粧料が提供される。According to the present invention, there is provided a cosmetic for hair having an excellent blood flow promoting effect and excellent safety.
Claims (2)
ジメチルアミンオキシド 【化1】 を含んでなる頭髪用化粧料。1. A blood flow promoting component and dimethylamine oxide represented by the following formula (I): A hair cosmetic composition comprising:
ジル類及びセンブリ抽出物からなる群の血流促進成分か
ら選ばれる1種又は2種以上の血流促進成分である請求
項1記載の頭髪用化粧料。2. The hair according to claim 1, wherein the blood flow promoting component is one or more blood flow promoting components selected from the group consisting of nicotinic acids, minoxidil and assembly extracts. Cosmetics.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9098447A JPH10279437A (en) | 1997-03-31 | 1997-03-31 | Hair cosmetic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9098447A JPH10279437A (en) | 1997-03-31 | 1997-03-31 | Hair cosmetic |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10279437A true JPH10279437A (en) | 1998-10-20 |
Family
ID=14219997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9098447A Withdrawn JPH10279437A (en) | 1997-03-31 | 1997-03-31 | Hair cosmetic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10279437A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11349451A (en) * | 1998-06-08 | 1999-12-21 | Taisho Pharmaceut Co Ltd | Hair grower |
WO2000064405A3 (en) * | 1999-04-22 | 2001-05-03 | Unilever Plc | Treating hair by targeting enzymes |
WO2001034102A1 (en) * | 1999-11-08 | 2001-05-17 | Shiseido Company, Ltd. | Scalp and hair care compositions |
JP2002512192A (en) * | 1998-04-22 | 2002-04-23 | ソルテック リサーチ プロプライアタリィ リミティド | Pharmaceutical composition |
JPWO2002092092A1 (en) * | 2001-05-15 | 2004-10-21 | 大正製薬株式会社 | Minoxidil-containing liquid composition |
ES2315115A1 (en) * | 2006-07-31 | 2009-03-16 | Jose Ignacio Navarro Sanchez | New capillary concentrate solution based on minoxidil. (Machine-translation by Google Translate, not legally binding) |
US10123966B2 (en) | 2013-05-16 | 2018-11-13 | The Procter And Gamble Company | Hair thickening compositions and methods of use |
-
1997
- 1997-03-31 JP JP9098447A patent/JPH10279437A/en not_active Withdrawn
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512192A (en) * | 1998-04-22 | 2002-04-23 | ソルテック リサーチ プロプライアタリィ リミティド | Pharmaceutical composition |
JP2007137899A (en) * | 1998-04-22 | 2007-06-07 | Connetics Australia Pty Ltd | Medicinal solution |
JPH11349451A (en) * | 1998-06-08 | 1999-12-21 | Taisho Pharmaceut Co Ltd | Hair grower |
WO2000064405A3 (en) * | 1999-04-22 | 2001-05-03 | Unilever Plc | Treating hair by targeting enzymes |
US6399052B2 (en) | 1999-04-22 | 2002-06-04 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Treating hair by targeting enzymes |
WO2001034102A1 (en) * | 1999-11-08 | 2001-05-17 | Shiseido Company, Ltd. | Scalp and hair care compositions |
JPWO2002092092A1 (en) * | 2001-05-15 | 2004-10-21 | 大正製薬株式会社 | Minoxidil-containing liquid composition |
ES2315115A1 (en) * | 2006-07-31 | 2009-03-16 | Jose Ignacio Navarro Sanchez | New capillary concentrate solution based on minoxidil. (Machine-translation by Google Translate, not legally binding) |
ES2315115B1 (en) * | 2006-07-31 | 2009-12-30 | Desarrollo Biotecnologico, S.L. | NEW CAPILLARY SOLUTION CONCENTRATED BASED ON MINOXIDIL. |
US10123966B2 (en) | 2013-05-16 | 2018-11-13 | The Procter And Gamble Company | Hair thickening compositions and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07316023A (en) | Hair tonic | |
JP4554805B2 (en) | Hair nourishing | |
JP2001288043A (en) | Composition for scalp and hair | |
JP3220761B2 (en) | Hair restoration | |
JPH10279437A (en) | Hair cosmetic | |
JPH11269043A (en) | Cosmetic for scalp and hair | |
JPH11269042A (en) | Cosmetic for scalp and hair | |
JP2002080327A (en) | Hair grower | |
JP2001288048A (en) | Composition for scalp and hair | |
JP2001288046A (en) | Composition for scalp and hair | |
JPH11302131A (en) | Cosmetic for scalp and hair | |
JP2001288045A (en) | Composition for scalp and hair | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
JPH11255621A (en) | Cosmetic for scalp and hair | |
JPH10273424A (en) | Cosmetic for hair | |
JPH10273423A (en) | Cosmetic for hair | |
JP2566792B2 (en) | Hair growth and hair growth promoter | |
EP0679385B1 (en) | Hair revitalizing composition | |
JPH0640858A (en) | Hair tonic | |
JPH11322545A (en) | Cosmetic for scalp and hair | |
JPH11263714A (en) | Cosmetic for scalp and hair of head | |
JP2862623B2 (en) | Hair restoration | |
JPH11302128A (en) | Cosmetic for scalp and hair | |
JP4327989B2 (en) | Hair cosmetics | |
JPH07149614A (en) | Hair tonic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20040601 |